Abstract | BACKGROUND: METHODS:
CADASIL patients (n=16) were treated with ACZ (250 mg) daily for 24 weeks. The mean blood flow velocity (MFV) of the middle cerebral artery (MCA) and CO(2)-induced cerebrovascular reactivity (CVR) were tested using transcranial Doppler sonography (TCD) before and after treatment. RESULTS: After ACZ treatment, the MFV in the MCA was significantly greater at rest (57.68+/-12.7 cm/s versus 67.12+/-9.4 cm/s; P=0.001). Additionally, the CO(2)-induced vasoreactivity increased significantly (13.17+/- 6.9% versus 20.69+/-8.2%, P=0.004), and the pulsatility index (PI) decreased significantly (0.82+/-0.1 versus 0.73+/-0.08; P=0.001). The relative ACZ-induced enhancement of CO(2) vasoreactivity was not correlated with pretreatment MFV (SRCC=-0.122; P=0.659). CONCLUSIONS: The present study provides the first evidence that ACZ therapy can increase CBF and CVR in CADASIL patients.
|
Authors | Li Huang, Qidong Yang, Le Zhang, Xuan Chen, Qing Huang, Hongxing Wang |
Journal | Journal of the neurological sciences
(J Neurol Sci)
Vol. 292
Issue 1-2
Pg. 77-80
(May 15 2010)
ISSN: 1878-5883 [Electronic] Netherlands |
PMID | 20227091
(Publication Type: Journal Article)
|
Copyright | Copyright 2010 Elsevier B.V. All rights reserved. |
Chemical References |
- Carbonic Anhydrase Inhibitors
- Acetazolamide
|
Topics |
- Acetazolamide
(therapeutic use)
- Adult
- Blood Flow Velocity
(drug effects)
- CADASIL
(diagnostic imaging, drug therapy)
- Carbonic Anhydrase Inhibitors
(therapeutic use)
- Cerebrovascular Circulation
(drug effects)
- Female
- Hemodynamics
(drug effects)
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Middle Cerebral Artery
(diagnostic imaging, drug effects)
- Patient Selection
- Pilot Projects
- Treatment Outcome
- Ultrasonography
|